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Abstract (234 words) 23 
There are currently no approved therapeutics or vaccines to treat or protect against the severe 24 
hemorrhagic fever and death caused by Ebola virus (EBOV). Ebola virus-like particles (EBOV-25 
VLPs) consisting of the matrix protein VP40, the glycoprotein (GP) and the nucleoprotein (NP) 26 
are highly immunogenic and protective in non-human primates against Ebola virus disease 27 
(EVD). We have constructed a modified vaccinia virus Ankara-Bavarian Nordic® (MVA-BN®) 28 
recombinant co-expressing VP40 and glycoprotein (GP) of EBOV Mayinga and the 29 
nucleoprotein (NP) of Taï Forest virus (TAFV) (MVA-BN-EBOV-VLP) to launch non-infectious 30 
EBOV-VLPs as a second vaccine modality in the MVA-BN-EBOV-VLP-vaccinated organism. 31 
Human cells infected with either MVA-BN-EBOV-VLP or MVA-BN-EBOV-GP showed 32 
comparable GP expression levels and transport of complex N-glycosylated GP to the cell 33 
surface. Human cells infected with MVA-BN-EBOV-VLP produced large amounts of EBOV-34 
VLPs that were decorated with GP spikes but excluded the poxviral membrane protein B5, thus 35 
resembling authentic EBOV particles. The heterologous TAFV-NP enhanced EBOV-VP40-36 
driven VLP formation with comparable efficiency as the homologous EBOV-NP in a transient 37 
expression assay, and both NPs were incorporated into EBOV-VLPs. EBOV-GP-specific CD8 T 38 
cell responses were comparably efficient between MVA-BN-EBOV-VLP and MVA-BN-EBOV-39 
GP immunized mice. The levels of EBOV-GP-specific neutralizing and binding antibodies as 40 
well as GP-specific IgG1/IgG2a ratios induced by the two constructs in mice were also similar, 41 
raising the question whether the quality rather than the quantity of the GP-specific antibody 42 
response might be altered by an EBOV-VLP-generating MVA recombinant.  43 
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Importance (148 words) 44 
The recent outbreak of Ebola virus (EBOV), claiming more than 11,000 lives, has underscored 45 
the need to advance the development of safe and effective filovirus vaccines. Virus-like particles 46 
(VLPs) as well as recombinant viral vectors have proved to be promising vaccine candidates. 47 
Modified vaccinia virus Ankara-Bavarian Nordic® (MVA-BN®) is a safe and immunogenic 48 
vaccine vector with a large capacity to accommodate multiple foreign genes. In this study, we 49 
combined the advantages of VLPs and the MVA platform by generating a recombinant MVA-50 
BN-EBOV-VLP that would produce non-infectious EBOV-VLPs in the vaccinated individual. Our 51 
results show that human cells infected with MVA-BN-EBOV-VLP indeed formed and released 52 
EBOV-VLPs, thus producing a highly authentic viral immunogen. MVA-BN-EBOV-VLP efficiently 53 
induced EBOV-specific humoral and cellular immune responses in vaccinated mice. These 54 
results are the basis for future advancements, e.g. by including antigens from various filoviral 55 
species to develop multivalent VLP-producing MVA based filovirus vaccines. 56 
 57 
Introduction 58 
Most members of the family Filoviridae including ebolaviruses and marburgviruses cause 59 
severe hemorrhagic fevers with high fatality rates in humans and great apes (1,2). The genus 60 
Ebolavirus contains five virus species including Zaire ebolavirus and Taï Forest ebolavirus. The 61 
genomes of the members of these five species differ by more than 30% at the nucleotide level 62 
(3). Ebola virus (EBOV) is the type virus of the species Zaire ebolavirus and has been 63 
responsible for most of the known outbreaks of Ebola virus disease (EVD) in Africa. The case-64 
fatality rate of this ebolavirus species ranges up to 90%, while only one human case of Taï 65 
Forest Virus (TAFV) infection has been reported so far that was non-fatal. However, TAFV 66 
infection can be lethal for cynomolgus macaques (4). The 2014/2015 epidemic of EVD in West 67 
Africa caused by a regional EBOV variant named Makona demonstrated that ebolaviruses not 68 
only give rise to locally restricted outbreaks but can also cause large and disastrous epidemics. 69 
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A total of 28 616 cases, including 11 310 deaths, have been counted during the recent West 70 
African Ebola epidemic (5). A number of vaccines against EVD are currently under development 71 
comprising virus-like particles (VLPs), an inactivated genetically modified EBOV, and various 72 
viral vectors, which include modified vaccinia virus Ankara-BN® (MVA-BN®), human and 73 
chimpanzee adenovirus, and vesicular stomatitis virus (VSV)(6-10).  74 
EBOV-VLPs purified from the supernatant of cells expressing EBOV-GP, -VP40 and -NP have 75 
been demonstrated to protect non-human primates (NHP) against lethal challenge with the 76 
homologous EBOV (11). The EBOV matrix protein VP40 alone is able to drive the generation of 77 
filovirus-like particles with the typical filamentous morphology, but lacking the GP surface spikes 78 
of bona fide EBOV virions (12-15). Since EBOV-GP is the critical target antigen for the induction 79 
of protective immune responses (16,17), a minimal Ebola VLP vaccine should include GP and 80 
VP40. Moreover, GP enhances the efficacy of VP40-driven VLP formation, which can be further 81 
stimulated by co-expressing other EBOV proteins, in particular NP, but also VP30 and VP24 82 
(18,19). Such EBOV-VLPs are non-infectious and thus safe since they lack viral genomic 83 
nucleic acid. 84 
MVA-BN is a highly replication-restricted vaccinia virus derived from its replication-competent 85 
ancestor chorioallantois vaccinia virus Ankara by over 570 passages in chicken embryo cells 86 
(20). A large body of preclinical and clinical evidence is supporting the conclusion that MVA-BN 87 
is a safe and immunogenic vaccine, which has paved the way for the approval of MVA-BN (21) 88 
as a smallpox vaccine in the European Union and Canada. In addition, numerous MVA 89 
recombinants have been shown to efficiently induce immune responses in animals and humans 90 
against heterologous antigens (22,23). Recently, a recombinant MVA-BN expressing EBOV-GP 91 
together with other filovirus antigens was shown in human trials to efficiently enhance humoral 92 
and cellular responses directed to EBOV-GP, if used as prime or boost vaccination in 93 
combination with human or chimpanzee adenoviral vectors (7,9). This demonstrates the 94 
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potential of MVA-BN as a vaccine platform to protect against lethal hemorrhagic fevers of 95 
humans like EVD in combination with a heterologous viral vector. 96 
To mimic the authentic structure of GP, the most relevant EVD vaccine antigen, as accurately 97 
as possible, we designed a recombinant MVA-BN vector vaccine generating EBOV-VLPs in the 98 
vaccinated organism. Such VLPs would provide a second vaccine modality in the vaccinated 99 
individual in addition to the vector-driven cell-restricted expression of EBOV proteins. Here, we 100 
describe a recombinant MVA-BN (MVA-BN-EBOV-VLP) that was engineered to express EBOV-101 
VP40 along with EBOV-GP and TAFV-NP in infected cells. The TAFV version of NP was 102 
chosen to provide for a broader representation of T cell antigens from different ebolavirus 103 
species in the vaccine construct. This recombinant virus directed the release of EBOV-VLPs 104 
that were densely decorated with EBOV-GP on their surface into the supernatant of infected 105 
cells, demonstrating that EBOV-VLP morphogenesis was compatible with the MVA platform. NP 106 
from EBOV and TAFV both enhanced the formation of VLPs driven by EBOV-VP40 and were 107 
found in VLPs. MVA-BN-EBOV-VLPs efficiently induced GP-specific cellular and humoral 108 
immune responses in mice, which were quantitatively comparable to those induced by MVA-BN-109 
EBOV-GP expressing only GP.  110 
 111 
Materials and Methods 112 
Cells, viruses and antibodies 113 
The human cervical carcinoma HeLa (CCL-2), human embryonic kidney HEK 293T/17 (CRL-114 
11268) and baby hamster kidney BHK-21 (CCL-10) cell lines cells were obtained from ATCC, 115 
Vero E6 cells were obtained from the European Cell Culture Collection via Sigma (cat no. 116 
85020206). All cell lines were cultivated in Dulbecco’s modified Eagle medium (DMEM, 117 
Gibco/Invitrogen, Darmstadt, Germany) supplemented with 10% fetal calf serum (FCS, Pan 118 
Biotech, Aidenbach, Germany). Primary chicken embryo fibroblast (CEF) cells were prepared 119 
from 11 day-old embryonated chicken eggs and cultured in VP-SFM (Gibco) for virus stock 120 
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production or in RPMI supplemented with 7% FCS for titration assays. The MVA used in this 121 
study was either MVA-BN® (Bavarian Nordic GmbH, Munich) or an MVA wild-type (wt), which 122 
was derived from a bacterial artificial chromosome (BAC) clone constructed from MVA-BN. The 123 
properties of the latter, containing a BAC cassette including an NPT II-IRES-enhanced green 124 
fluorescent protein (EGFP) array of selectable markers, were indistinguishable from those of 125 
MVA-BN (24). MVA-BN, MVA-BN recombinants and MVA wt were propagated on primary or 126 
secondary CEF cells and titrated on secondary CEF cells using the TCID50 method as described 127 
(25). The murine monoclonal antibodies 6D8 against EBOV GP and 9G4 against Marburg virus 128 
(MARV)-Musoke GP were obtained from J. Biggins (US Army Medical Research Institute of 129 
Infectious Diseases, Fort Detrick, MD, USA). The anti-TAFV-NP antibody was generated for 130 
Bavarian Nordic by BioGenes GmbH, Berlin, Germany, against a TAFV-NP-derived peptide with 131 
the sequence CVSGSENTDNKPHSE. Rabbit polyclonal anti-EBOV-NP (#0301-012) and anti-132 
EBOV-VP40 (#0301-010) antibodies were obtained from IBT Bioservices, Gaithersburg, MD, 133 
USA. The rabbit polyclonal B5-specific antibody was a gift from Dr. Robert Drillien, I.G.B.M.C., 134 
67400 Illkirch-Graffenstaden, France. 135 
 136 
Generation of recombinant viruses 137 
MVA-BN-EBOV-GP and MVA-BN-EBOV-VLP recombinants were generated using transient 138 
dominant selection (26)  according to standard procedures. The cDNAs encoding VP40 and GP 139 
of Zaire ebolavirus variant Mayinga and NP of Taï Forest ebolavirus (TAFV) were synthesized 140 
by Invitrogen GeneArt (Regensburg, Germany). The recombinant viruses still contained the 141 
NPT II/RFP cassette (MVA-BN-EBOV-GP) or both cassettes (MVA-BN-EBOV-VLP). 142 
Recombinant EBOV-VP40 and TAFV-NP expression was driven by the PrS promoter (27) while 143 
the EBOV-GP gene was under control of the PrS5E promoter containing five additional tandem 144 
repeats of the p7.5k promoter (28) in both MVA recombinants. A recombinant chimeric VSV 145 
(VSV-EBOV-GP) was generated by replacing the VSV G gene with the EBOV-GP gene (variant 146 
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Mayinga) according to published procedures (29). VSV-EBOV-GP also expressed EGFP from 147 
an additional transcription cassette downstream of the GP gene. In addition, VSV-EBOV-GP 148 
encoded for a modified VSV-M gene containing 4 point mutations (MQ) known to reduce 149 
cytotoxicity of the virus and to induce type I IFN in IFN-competent cells (30). VSV-EBOV-GP 150 
was propagated and titrated on Vero and BHK-21 cells. 151 
 152 
Transient transfections 153 
cDNAs optimized for human codon usage encoding EBOV-VP40, EBOV-NP and TAFV-NP 154 
were synthesized by GeneArt (Regensburg, Germany) and subcloned into MVA recombination 155 
plasmids  (Bavarian Nordic, Munich, Germany) under the control of the synthetic PrS vaccinia 156 
virus promoter. For cellular expression, subconfluent cells in 12-well tissue culture plates were 157 
infected with MVA-BN® at a multiplicity of infection (MOI) of 5. At 1 h post infection (p.i.), cells 158 
were transfected with FuGene® HD/6 (Promega, Mannheim, Germany) according to 159 
manufacturer’s instructions, using a total of 3 µg plasmid DNA and 9 µl of transfection reagent 160 
per well. 161 
 162 
Glycosylation analysis 163 
Infected cells were lysed in RIPA buffer (New England Biolabs, Frankfurt, Germany), cell lysates 164 
divided into three aliquots and treated with either Endo H or PNGase F (New England Biolabs, 165 
Frankfurt, Germany) according to manufacturer’s instructions or mock treated. For Western blot 166 
analysis, samples were mixed with 3x Laemmli sample loading buffer. 167 
 168 
Immunoblot analysis EBOV and TAFV proteins 169 
HeLa and HEK 293T/17 cells were seeded on the day before infection. Inoculation, cell lysate 170 
preparation, immunoblotting, immunodetection and stripping were performed as previously 171 
described (31). For SDS-PAGE, 7.5% Mini-Protean TGX polyacrylamide gels were used (Bio-172 
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Rad, Munich, Germany). Antibodies used for immunodetection were diluted as follows: anti-173 
EBOV-GP mAb 6D8, anti-EBOV-VP40 and anti-EBOV-NP 1:1000, anti-TAFV-NP 1:10,000. 174 
Detection of protein bands by enhanced chemiluminescence (ECL) was carried out with two 175 
alternative substrate reagents depending on signal strength, SuperSignal West Pico (Thermo 176 
Scientific, Bonn, Germany) as the standard reagent and ECL Advance Western Blotting 177 
Detection Kit (GE Healthcare, Munich, Germany) for detection with higher sensitivity. Western 178 
blot images were acquired using Kodak BioMax Light Films (Sigma-Aldrich, Munich, Germany) 179 
or the ChemiDoc Touch System and Image Lab™ Software (Bio-Rad, Munich, Germany) for 180 
image analysis and quantification.  181 
 182 
Reverse transcriptase quantitative real-time PCR 183 
Infection/transfection controls for RT-qPCR were set up in triplicate per condition and RNA from 184 
1-1.5x106 infected HEK293T/17 cells per sample was isolated as previously described (32). 185 
Reverse transcription of 3 µl of isolated RNA was performed using the Omniscript RT kit 186 
(205113, Qiagen) in the presence of an RNase inhibitor (R2520, Sigma-Aldrich) at a final 187 
concentration of 10 U/µl for 70 min at 37°C using random nonamer primers at a final 188 
concentration of 5 µM (R7647, Sigma-Aldrich). 1 µl of RT reaction was added to 20 µl of total 189 
PCR reaction mixture for quantitative real-time PCR based on the TaqMan® Gene Expression 190 
Master Mix (4369016, Life Technologies, Darmstadt, Germany) according to the manufacturer’s 191 
instructions. Quantitative PCR of cDNA was performed using the following primers and 192 
TaqMan® probes: EBOV-NP fw primer: GCAGTCTGTCGGGCATATGA (final conc. 500 nM), 193 
EBOV-NP rev primer: CTTTCAGTCTTTTGGAGGATGTG (final conc. 500 nM), EBOV-NP 194 
probe: FAM-TCAAGGCATGCATATGGTCGCC- MGBNFQ (final conc. 252 nM), TAFV-NP fw 195 
primer: GAGCGTGGGCCACATGA (final conc. 500 nM), TAFV-NP rev primer: 196 
TCGGTTTTCTGCAGGATGTG (final conc. 500 nM), TAFV-NP probe: FAM-197 
CCAGGGAATGCACATGGTGGCT- MGBNFQ (final conc. 252 nM). The EBOV-NP- and TAFV-198 
 o
n
 April 5, 2017 by Universitaet Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
9 
 
 
NP-specific primer/probe sets were used as a 1:1 mix in a multiplex qPCR reaction. Input cDNA 199 
was normalized using TaqMan® gene expression assay 18S (Hs99999901_s1) detecting 200 
eukaryotic 18S rRNA transcripts. All real-time qPCR reactions were performed in duplicate 201 
using an Applied Biosystems 7500 Real-Time PCR System with initial incubation at 50°C for 2 202 
min (uracil DNA glycosylase activation), 10 min incubation at 95°C, and 40 cycles of 15 s at 203 
95°C and 1 min at 60°C. No-template controls and minus-RT controls were uniformly negative. 204 
Fold transcription of NP was calculated relative to cells not expressing NP. Ct values were 205 
arbitrarily set to 36 if Ct value was “undetermined” or > 36. 206 
 207 
Flow cytometry 208 
Infected and uninfected cell monolayers were washed with PBS and single cell suspensions 209 
were prepared by scraping and thoroughly resuspending the cells. Cells were washed and 210 
resupended in ice-cold PBS containing 2% FCS, stained using anti-EBOV-GP monoclonal 211 
antibody 6D8 (1:2500) followed by staining with an allophycocyanin-coupled anti-mouse 212 
secondary antibody (1:1000). Cells were analyzed for GP surface expression, as well as 213 
cytoplasmic EGFP and RFP expression by flow cytometry using a LSR II flow cytometer (BD 214 
Biosciences, Heidelberg, Germany) and FlowJo software (Tree Star Inc., Ashland, OR, USA).  215 
 216 
Preparation of EBOV-VLPs 217 
EBOV-VLPs in supernatants of MVA-BN-EBOV-VLP infected cells were concentrated and 218 
purified by centrifugation through a 20% sucrose cushion at 36,000 rpm in a Beckmann SW41 219 
rotor for 2 h. The pellet was thoroughly resuspended in ice-cold PBS containing protease 220 
inhibitor cocktail (Roche cOmplete; Sigma-Aldrich, Munich, Germany), by initial vortexing and 221 
then rotating the samples for 1 h at 4°C. 222 
 223 
Confocal immunofluorescence analysis of recombinant EBOV protein expression 224 
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HeLa cells were grown on 12 mm coverslips (0.17 mm thick), infected at a MOI of 10 with the 225 
recombinant MVA vectors and fixed 6 h p.i. with 3.7% formaldehyde in PBS. After 226 
permeabilization with PBS containing 0.1% Triton X-100, the cells were blocked with PBS 227 
supplemented with 3% bovine serum albumin (PBS-BSA). Cells were incubated with the 228 
corresponding antibodies diluted in PBS-BSA: murine monoclonal antibody 6D8 against EBOV-229 
GP 1:200, rabbit polyclonal anti-TAFV-NP antibody 1:500, rabbit polyclonal anti-EBOV-VP40 230 
1:250. As secondary antibodies, goat anti-rabbit IgG (H+L)-Alexa Fluor 405 or goat anti-mouse 231 
IgG(H+L)-Alexa Fluor 633 (Molecular Probes, Invitrogen, USA) were used at a dilution of 1:500. 232 
After washing with PBS and H2O, the coverslips were mounted in Prolong Gold (Molecular 233 
Probes, Invitrogen, USA). Samples were analyzed using a confocal laser-scanning microscope 234 
SP8 (Leica Microsystems, Wetzlar, Germany, 63x oil objective). 235 
 236 
Immunoelectron microscopy 237 
For immunoelectron microscopy (immuno-EM), samples were adsorbed to carbon-coated 238 
parlodion films mounted on 300 mesh/inch copper grids (EMS, Fort Washington, PA, USA) for 239 
10 min, blocked with PBS containing 0.1% BSA (PBS-BSA/0.1%) for 10 min, incubated with the 240 
primary antibody diluted in PBS-BSA/0.1% (murine monoclonal antibody 6D8 against EBOV-GP 241 
1:50, murine monoclonal antibody 9G4 against MARV-GP 1:50, rabbit polyclonal anti-B5 1:400) 242 
for 1 hour, washed several times with PBS-BSA/0.1%, incubated with the secondary anti-IgG 243 
antibody coupled to 12 or 18 nm colloidal gold particles (Jackson ImmunoResearch, West 244 
Grove, PA, USA) diluted 1:15 (18 nm) or 1:30 (12 nm) in PBS-BSA/0.1%, washed several times 245 
with PBS and H2O and stained with 2% phosphotungstic acid (PTA), pH 7.0 (Aldrich, Steinheim, 246 
Germany) for 1 min. Specimens were analyzed in a transmission electron microscope (CM12, 247 
Philips, Eindhoven, Netherlands) equipped with a CCD camera (Ultrascan 1000, Gatan, 248 
Pleasanton, CA, USA) at an acceleration voltage of 100 kV. 249 
 250 
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Preparation and analysis of ultrathin sections 251 
HeLa cells either grown on sapphire disk or in 6-well tissue culture plates were infected at a 252 
MOI of 10 with the recombinant MVA vectors. After 12-24 h, the cells were either scraped into 253 
the medium and the cell pellet was fixed in 2.5% glutaraldehyde (GA) by centrifugation for 20 254 
min at 4000 g, or the sapphire disks were fixed in 2.5% GA for 1 hour at 4 °C before embedding 255 
in epon according to a standard protocol (33). Briefly, after fixation with 2.5% GA, cells were 256 
postfixed with 1% osmium tetroxide (OsO4), dehydrated in a graded ethanol series starting at 257 
70% and, after two changes in acetone, embedded in epon. Ultrathin sections were stained with 258 
uranyl acetate and lead citrate and were analyzed in a transmission electron microscope as 259 
described above. (CM12, Philips, Eindhoven, Netherlands) equipped with a CCD camera 260 
(Ultrascan 1000, Gatan, Pleasanton, CA, USA) at an acceleration voltage of 100 kV.  261 
 262 
Enzyme-linked immunosorbent assay (ELISA) and plaque reduction neutralization test 50 263 
(PRNT50) 264 
For immunization 6-8 week-old CBA mice (Janvier Labs, Le Genest Saint Isle, France) were 265 
used (group size n=5). The animals were immunized intramuscularly into the hind leg with 108 266 
TCID50 of either MVA-BN-EBOV-GP or MVA-BN-EBOV-VLP in 50 µl sterile PBS on days 0 and 267 
28. Blood samples were taken on days 21, 42 and 56 and serum was prepared to determine 268 
Ebola virus GP-specific IgGs by direct ELISA. 96-well plates were coated overnight with 269 
recombinant EBOV-GP antigen (total IgG, 0.625 µg/ml; IgG1, 0.64 µg/ml; IgG2a 0.32 µg/ml) 270 
(IBT Bioservices, Rockville, MD, USA). Test sera were titrated in duplicate using twofold serial 271 
dilutions. The plates were incubated for 1 h at room temperature, washed and incubated for 1 h 272 
with detection antibody sheep or goat anti-mouse IgG-HRP, IgG1-HRP or IgG2a-HRP (1:2,000 273 
dilution) (Bio-Rad, Munich, Germany). Plates were washed and developed using 3.3′5.5′-274 
tetramethylbenzidine at room temperature in the dark, the reaction was stopped after 30 min 275 
 o
n
 April 5, 2017 by Universitaet Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
12 
 
 
(total IgG) or 15 min (IgG1/2a) using H2SO4 and read out at 450 nm (TECAN Sunrise ELISA 276 
plate reader). 277 
For PRNT50, a chimeric VSV construct in which the authentic G spike glycoprotein was 278 
replaced by EBOV-GP was used to determine the titer of EBOV-neutralizing antibodies in sera 279 
of immunized mice. Serial dilutions of mouse antiserum were incubated in duplicate with ~100-280 
150 pfu of VSV-EBOV-GP per dilution and plated on Vero cells for three days. The monolayers 281 
were stained with crystal violet and scanned with a flat bed scanner. The electronic images of 282 
the monolayers were then analyzed by neuronal network software (NN plate count, developed 283 
in-house) recognizing and counting the plaques and calculating the PRNT50.  284 
Results were analyzed by an unpaired two-tailed Student´s t test. p-values of < 0.05 were 285 
considered statistically significant. 286 
 287 
EBOV-GP-specific CD8 T cell response 288 
CBA mice were immunized by intramuscular (i.m.) or intravenous (i.v.) application of 108 TCID50 289 
of MVA-BN-EBOV-GP or MVA-BN-EBOV-VLP on days 0 and 28 (group size n=5). The CD8 T 290 
cell response against the immunodominant GP epitope in the H-2k haplotype (TELRTFSI) was 291 
determined by dextramer staining of peripheral blood mononuclear cells on days 8 and 5 after 292 
prime and boost, respectively. For intracellular cytokine staining, immunized mice were 293 
sacrificed at d56 (28 days after the last immunization), spleens were harvested on ice and 294 
mononuclear spleen cell suspensions were prepared. Cells were incubated with 5 μg/ml of MHC 295 
class I restricted EBOV-GP-derived peptide (TELRTFSI) (GenScript, Piscataway, NJ, USA) for 296 
5–6 h at 37°C in complete RPMI in the presence of 1 μl/ml GolgiPlug (BD Biosciences, 297 
Heidelberg, Germany), and anti-CD107 (FITC) (BioLegend, San Diego, CA, USA). Cell surface 298 
marker expression was analyzed with anti-CD4 (BV650), anti-CD8 (BV785) (both BioLegend) 299 
and anti-CD44 (APC-eFluor780) (eBiosciences, San Diego, CA, USA) antibodies. For live/dead 300 
cell discrimination, cells were stained with LIVE/DEAD fixable aqua dead cell staining kit 301 
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according to the manufacturer’s instructions (Life Technologies GmbH, Darmstadt, Germany). 302 
Intracellular cytokine staining of IFN-γ (PE-Cy7), TNF-α (PerCP-eFluor710) and IL-2 (APC) (all 303 
eBiosciences) was performed after fixation and permeabilization according to the 304 
manufacturer’s instructions (BD Cytofix/Cytoperm, BD Biosciences). Flow cytometric analysis 305 
was performed using a digital LSR II (BD Biosciences). Data were analyzed with FlowJo 306 
software (Tree Star Inc., Ashland, OR, USA). Results were analyzed by an unpaired two-tailed 307 
Student´s t test. p-values of < 0.05 were considered statistically significant. 308 
 309 
 310 
Results 311 
Recombinant MVA constructs MVA-BN-EBOV-GP and MVA-BN-EBOV-VLP 312 
The aim of this study was to generate a recombinant MVA-BN vector to protect against EVD 313 
that not only expresses the major protective antigen GP but that also triggers the production of 314 
EBOV-VLPs in infected cells. For this, the genes encoding VP40 and GP, both derived from the 315 
Mayinga variant of EBOV, and NP derived from TAFV were inserted into intergenic regions 316 
(IGRs) of MVA-BN® under the control of the early/late vaccinia virus promoters PrS and PrS5E 317 
(Fig. 1A). PrS5E contains the PrS compact synthetic early/late promoter and five additional 318 
Pr7.5 early elements (27,28).  319 
Expression of EBOV-GP was studied by Western blot analysis of cell lysates from HeLa cells 320 
infected with MVA-BN-EBOV-GP or MVA-BN-EBOV-VLP. Two distinct bands were observed in 321 
lysates of cells infected with either MVA-BN-EBOV-GP or MVA-BN-EBOV-VLP (Fig. 1B). The 322 
upper band detected at 6 h and 24 h p.i. (Fig. 1B, lanes 3 to 6) likely represents the mature, fully 323 
N- and O-glycosylated GP which has been proteolytically cleaved into the large subunit GP1 and 324 
the small subunit GP2. GP2 was not recognized by the antibody used. In addition, the mature 325 
GP1 could not be distinguished from the uncleaved and fully glycosylated precursor GP (preGP) 326 
due to the very similar migration of these two forms in our SDS-PAGE system. The lower band 327 
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(Fig. 1B, lanes 3, 5) was detected at 6 h but not at 24 h p.i. and presumably represents the 328 
immature and unprocessed GP precursor protein residing in the endoplasmic reticulum (pre-329 
GPER) (34,35). GP1 and the uncleaved precursor preGP have a larger apparent molecular 330 
weight than preGPER due to extensive O-glycosylation and maturation of the N-glycans from the 331 
high-mannose to the complex-type form (35,36). Lysates of cells infected with MVA-BN-EBOV-332 
GP or MVA-BN-EBOV-VLP revealed a very similar pattern of EBOV-GP-specific bands 333 
indicating similar GP processing and maturation (Fig. 1B).  334 
To further characterize the two major forms of recombinant EBOV-GP, we analyzed N-335 
glycosylation of the protein by using two different endoglycosidases. Endoglycosidase H (Endo 336 
H) removes N-glycans of the high-mannose type which have been co-translationally attached to 337 
the protein in the ER. During transport of glycoproteins through the Golgi apparatus, their N-338 
glycans are further processed to the complex type, rendering them resistant to Endo H. Both, 339 
ER- and Golgi-resident N-glycans are sensitive to PNGase F, which removes high-mannose, 340 
hybrid, as well as complex N-glycans. However, O-linked glycans, which are added to EBOV-341 
GP in the Golgi apparatus, are not susceptible to either of the two enzymes. HeLa cell lysates 342 
prepared 17 h p.i. with MVA-BN-EBOV-GP or MVA-BN-EBOV-VLP were either mock-treated or 343 
incubated with Endo H or PNGase F and analyzed by immunoblot (Fig. 1C). The upper band, 344 
likely representing GP1/preGP, turned out to be resistant to Endo H-mediated deglycosylation, 345 
indicating that this GP form had left the ER and entered the Golgi apparatus. In contrast, the 346 
faster migrating band, presumably representing uncleaved preGPER (35,36) was clearly affected 347 
by Endo H digestion, indicating that a proportion of EBOV-GP still resided in the ER late in 348 
infection (Fig. 1C, lanes 2 and 5). We were not able to distinguish between GP1 and Endo H-349 
resistant preGP in our gel system. Treatment with PNGase F affected the migration of both the 350 
upper and the lower EBOV-GP band and generated an additional GP species that migrated in 351 
the gel as a broad and prominent smear (Fig. 1C, lanes 3 and 6), likely representing the de-N-352 
glycosylated but still O-glycosylated EBOV-GP.  353 
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Flow cytometric analysis of HeLa cells infected with either MVA-BN-EBOV-GP or MVA-BN-354 
EBOV-VLP showed that EBOV-GP was already present at the cell surface in large amounts at 355 
4 h p.i. (Fig. 1D). EBOV-GP levels were only slightly increased when the cells were analyzed 24 356 
h p.i. No significant differences in EBOV-GP cell surface expression levels were detected 357 
between cells infected with MVA-BN-EBOV-GP and MVA-BN-EBOV-VLP.  358 
In addition to expression of GP, HEK 293T/17 cells infected with MVA-BN-EBOV-VLP also 359 
expressed EBOV-VP40 and TAFV-NP as indicated by detection of specific bands in 360 
immunoblots at approximately 40 kDa and 100 kDa, respectively (Fig. 1E). In summary, no 361 
obvious differences in intracellular and cell surface expression levels and glycosylation of 362 
EBOV-GP were observed throughout the time course of infection with MVA-BN-EBOV-GP and 363 
MVA-BN-EBOV-VLP (Fig. 1B-D). These results indicate that neither any MVA-BN factors nor 364 
co-expression of VP40 and NP interfered with the transport or N-glycosylation of EBOV-GP 365 
along the secretory pathway.  366 
 367 
Intracellular distribution of Ebola proteins in MVA-BN-EBOV-VLP infected cells 368 
Confocal laser-scanning microscopy was used to examine the synthesis and subcellular 369 
localization of EBOV-GP, EBOV-VP40 and TAFV-NP with specific antibodies (Fig. 2). EGFP 370 
fluorescence (selection marker in MVA-BN-EBOV-VLP or MVA wt, shown in grey) and RFP 371 
fluorescence (selection marker in MVA-BN-EBOV-VLP or MVA-BN-EBOV-GP, shown in grey) 372 
were used to identify vector infected cells. In both, cells infected with MVA-BN-EBOV-VLP or 373 
MVA-BN-EBOV-GP infected cells, EBOV-GP was mainly located at the cell membrane where it 374 
was present in long cellular protrusions (Fig. 2, first two panels, in green). Similar to EBOV-GP, 375 
the matrix protein EBOV-VP40 was strongly associated with the cell membrane (Fig. 2, middle 376 
two panels, in magenta). TAFV-NP formed large aggregates in the cytoplasm that resembled 377 
typical inclusion bodies (Fig. 2, last two panels, in cyan). In addition to these large NP 378 
aggregates, there were smaller aggregations of TAFV-NP that were closely associated with the 379 
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plasma membrane (Fig. 2, upper right panels). Since VP40 is also located mainly at or below 380 
the plasma (Fig. 2, upper middle panels) it is very likely that a fraction of VP40 and NP 381 
colocalized, though this could not formally be proven due to technical constraints. Taken 382 
together, the subcellular localization of the MVA encoded ebolavirus proteins was consistent 383 
with previously published data (37) and further supports and extends our initial observation by 384 
confirming that MVA infection does not interfere with the intracellular distribution of GP, VP40 385 
and NP. 386 
 387 
Ebola VLPs in supernatants of MVA-BN-EBOV-VLP infected cells 388 
We prepared VLPs from supernatants of cells infected with MVA-BN-EBOV-VLP and analyzed 389 
these preparations as well as plain supernatants and cellular lysates for the presence of EBOV-390 
GP, EBOV-VP40 and TAFV-NP. Infections with MVA-BN-EBOV-GP and MVA-BN wt were 391 
included as controls (Fig. 3). Levels of GP were slightly higher in lysates of cells infected with 392 
MVA-BN-EBOV-GP when compared to MVA-BN-EBOV-VLP. EBOV-GP was detectable in 393 
supernatants and in sucrose cushion-purified supernatants from MVA-BN-EBOV-GP infected 394 
cells, indicative of GP release in form of pleomorphic particles as described previously (15,36). 395 
In comparison, GP levels were higher in the supernatants and VLP preparations from cells 396 
infected with MVA-BN-EBOV-VLP (Fig. 3). Thus, more GP was released upon co-expression of 397 
VP40 and TAFV-NP, most likely by formation of EBOV-VLPs. VP40 was also present in 398 
supernatants and was highly enriched in VLP preparations, indicating the formation of VP40-399 
driven VLPs by MVA-BN-EBOV-VLP infected cells (Fig. 3). The smaller VP40 forms most likely 400 
represent a translation product initiated at the internal methionine residue 14 and degradation 401 
products as previously described (38). TAFV-NP was also detectable in VLP preparations but 402 
not in plain supernatants, implying that TAFV-NP had been incorporated in a species 403 
independent manner into VLPs driven by EBOV-VP40 expression.  404 
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To obtain detailed visual information on MVA-driven EBOV-VLP formation, ultrathin sections of 405 
infected HeLa cells were analyzed by transmission electron microscopy (TEM). At 24 h p.i. with 406 
MVA-BN-EBOV-VLP, several longitudinal as well as cross sections through filamentous 407 
structures were detected which resembled typical EBOV virions at the stage of budding from the 408 
plasma membrane (Fig. 4A). These virus-like structures differed from cellular filopodia by their 409 
consistently smaller diameter. Cellular filopodia were also present in MVA infected control cells 410 
(Fig. 4B). Concentrated, purified VLP preparations from the supernatant of MVA-BN-EBOV-VLP 411 
infected cells revealed the release of filamentous particles typical for EBOV-VLPs (Fig. 4C). 412 
Immuno-EM labeling with an EBOV-GP-specific monoclonal antibody resulted in the decoration 413 
of the surface of the filamentous particles with gold beads specifically identifying these particles 414 
as EBOV-VLPs (Fig. 4C). No labeling of the filamentous particles was detectable using a 415 
MARV-GP-specific antibody (data not shown), confirming specificity of the labeling reaction. The 416 
concentrated supernatant of MVA-BN-EBOV-GP infected cells contained some pleomorphic 417 
particles that were also labeled by the EBOV-GP-specific antibody (Fig. 4D). Such non-418 
filamentous EBOV-GP positive particles were also present in the supernatant of MVA-BN-419 
EBOV-VLP infected cells (Fig. 4C, bottom left) and were most likely the result of a GP-420 
dependent but VP40-independent budding process (15,36). In preparations of supernatant from 421 
MVA-BN infected cells, no GP positive particles were detected (Fig. 4E). These findings indicate 422 
that the filamentous particle shown in Fig. 4C represents a bona fide Ebola VLP which was 423 
released from MVA-BN-EBOV-VLP infected cells.  424 
 425 
Vaccinia virus protein B5 is excluded form EBOV-VLP 426 
Vaccinia virus encoded proteins of the outer membrane of the extracellular vaccinia virus (EV) 427 
including the B5 protein have been shown to partly localize to the plasma membrane of infected 428 
cells (39). We therefore analyzed whether the B5 protein, an important component of the 429 
poxviral EV membrane, would also be incorporated into EBOV-VLPs. Double immunogold-430 
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labeling and TEM analysis of concentrated VLP preparations from MVA-BN-EBOV-VLP infected 431 
cells revealed that the B5 protein (18 nm gold particles) was exclusively localized in non-viral 432 
particulate structures that did not overlap with EBOV-GP positive particles (12 nm gold particles, 433 
Fig. 4F), suggesting that this MVA protein is excluded from VLPs. This also applied to the 434 
pleomorphic particles released from MVA-BN-EBOV-GP infected cells (Fig. 4G). After infection 435 
with MVA-BN, particulate structures were only stained by the 18 nm gold particle-conjugated 436 
antibody directed to B5 protein, but not with antibodies specifically recognizing the EBOV-GP 437 
(Fig. 4H). Most likely, the B5 protein positive structures represent membranous vesicles that 438 
were derived from cellular compartments like the Golgi apparatus, the trans-Golgi network, 439 
endosomes or the plasma membrane. These data confirm previous observations showing that 440 
the formation of ebolavirus-like particles at the plasma membrane is a specific process that 441 
excludes other proteins from incorporation into the VLPs (13,40,41). 442 
 443 
Incorporation of NP into EBOV-VLPs 444 
EBOV-NP is incorporated into VLPs formed by expression of homologous EBOV-VP40 (42,43). 445 
Although TAFV-NP was expressed along with EBOV-GP and EBOV-VP40 by HEK 293T/17 446 
cells infected with MVA-BN-EBOV-VLP (Fig. 1E, 3), cross-sections of EBOV-VLPs appeared to 447 
be “empty” (Fig. 4A), suggesting that the EBOV-VLPs produced by MVA-BN-EBOV-VLP did not 448 
contain nucleocapsid-like structures. In order to analyze whether TAFV-NP is incorporated into 449 
EBOV-VP40-derived VLPs and whether it can enhance VLP formation in a species-independent 450 
fashion, a VLP formation assay based on plasmid-based EBOV-NP and TAFV-NP expression in 451 
MVA infected cells was used. Plasmids encoding either TAFV-NP or EBOV-NP under the 452 
control of the vaccinia virus early-late promoter PrS were transfected into MVA infected HEK 453 
293T/17 cells along with a plasmid encoding EBOV-VP40 under the control of the same 454 
promoter.  455 
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Western blot analysis of the cell lysates demonstrated that VP40 levels were not grossly 456 
affected by co-expression of either EBOV-NP or TAFV-NP (Fig. 5A, top panel). To analyze 457 
whether NP and VP40 were released into the supernatant of transfected cells as part of VLPs, 458 
we removed soluble VP40 dimers and soluble NP by ultrafiltration through an Amicon® Ultra 100 459 
kDa cut-off filter. Analysis of such purified and concentrated supernatants showed that the 460 
amount of VLP-associated VP40 in purified supernatants was 3.2-fold enhanced by co-461 
expression of EBOV-NP. TAFV-NP enhanced VLP release by 2.7-fold, suggesting that both 462 
NPs did not significantly differ in this aspect (Fig. 5A, top panel). Compared to NP levels found 463 
in cell lysates, the proportion of VLP-associated NP in purified supernatants was also similar for 464 
both EBOV-NP (1/18) (Fig. 5A, middle panel) and TAFV-NP (1/21) (Fig. 5A, bottom panel). 465 
Because two different NP-specific antibodies had to be used for Western blot analysis of EBOV-466 
NP and TAFV-NP, expression levels of the NPs could not be directly compared. To provide 467 
indication for equal expression levels of both NPs, we confirmed that EGFP, which is co-468 
expressed from the NP-encoding plasmids, was present at similar levels (data not shown). In 469 
addition, TaqMan® RT-qPCR indicated that transcript levels of EBOV-NP and TAFV-NP were 470 
very similar (data not shown). Thus, the capacity of both TAFV-NP and EBOV-NP to enhance 471 
EBOV-VLP formation appeared to be very similar.  472 
The presence of B5 in non-viral particulate structures of EBOV-VLP preparations and in purified 473 
supernatants of MVA infected cells not generating EBOV-VLPs (Fig. 4F-H) was also confirmed 474 
by Western blot. Expression of filovirus proteins EBOV-VP40, EBOV-NP or TAFV-NP in MVA-475 
BN infected cells did not affect the release of B5 into supernatants (Fig. 5B) while VP40 release 476 
was enhanced by NP (Fig. 5A). This result supports the notion that B5 was not incorporated into 477 
VP40-driven EBOV-VLPs but was rather secreted by a different and spatially separated 478 
mechanism. Likely, B5 was contained in exosome-like vesicles that have previously been 479 
reported to be released from MVA infected cells (44). 480 
 481 
 o
n
 April 5, 2017 by Universitaet Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
20 
 
 
Detection of nucleocapsid-like structures in MVA-driven EBOV-VLPs  482 
Co-expression of NP with VP40 results in formation of a nucleocapsid-like structure visible as 483 
an inner ring in electron micrographs of VLP cross-sections (43), termed “bull´s eye” by Johnson 484 
et al. (43). We were unable to discern nucleocapsid-like structures in cross-sections of VLPs 485 
produced by cell infected with MVA-BN-EBOV-VLP (Fig. 4A and data not shown) although 486 
TAFV-NP was detected in VLPs as indicated by Western blot analysis (Fig. 3). Using the 487 
transfection approach described above, we compared the morphology of VLPs in ultrathin 488 
sections of HeLa cells expressing EBOV-VP40 along with either EBOV-NP or TAFV-NP. Cross-489 
sections of VLPs generated in the presence of EBOV-NP clearly revealed nucleocapsid-like ring 490 
structures (Fig. 6A), indicating that EBOV-NP has been incorporated into VLPs. In contrast, 491 
most VLPs generated in the presence of TAFV-NP either appeared empty (Fig. 6B, 4A) or were 492 
filled with an amorphous structure or sometimes with an irregular-shaped, but not ring-like 493 
structure (data not shown). When 18 cross sections through VLPs released from VP40 and 494 
EBOV-NP expressing cells were analyzed, 9 had a clear inner ring, 8 showed a central 495 
irregular-shaped structure and one was empty. In contrast, of 77 cross-sections of EBOV-VLPs, 496 
which were generated in the presence of TAFV-NP (either by MVA-BN-EBOV-VLP infection or 497 
by VP40/TAFV-NP plasmid-based co-expression), 65 were empty, 11 had some internal 498 
irregular structure and only two showed a ring-like structure.  499 
We conclude from these findings that the incorporation of NP into EBOV-VLPs and the 500 
enhancement of release of EBOV-VP40 VLPs occurs species-independent in the Ebolavirus 501 
genus (Fig. 3, 5A). The results from our EM analyses suggest, however, that the characteristic 502 
inner ring structure is efficiently formed only if the homologous EBOV-NP is present. 503 
 504 
Induction of GP-binding and neutralizing antibodies by MVA-BN-EBOV-VLP in mice 505 
Since EBOV-GP-specific antibody responses are considered most important for assessing the 506 
protective potential of EBOV vaccine candidates (16,17), we compared the induction of EBOV-507 
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GP-specific antibodies in CBA mice following immunization with MVA-BN-EBOV-VLP and MVA-508 
BN-EBOV-GP. Mice were vaccinated intramuscularly on days 0 and 28 and binding as well as 509 
neutralizing antibody responses on days 21, 42, and 56 were analyzed by ELISA and by PRNT 510 
using chimeric VSV-EBOV-GP as surrogate virus. Binding or neutralizing antibody titers of the 511 
immune sera from the two mouse groups did not significantly differ at any time point after 512 
priming or boosting (Fig. 7A, B and data not shown). To evaluate one qualitative aspect of the 513 
antibody response, we analyzed the levels of EBOV-GP-specific isotypes IgG1 and IgG2a. 514 
Although there appeared to be a tendency towards lower IgG1 and higher IgG2a levels of MVA-515 
BN-EBOV-VLP-induced GP-specific antibodies compared to the respective IgG1 and IgG2a 516 
titers induced by MVA-BN-EBOV-GP (Fig. 7C, D), all of these differences where not statistically 517 
significant and the tendency was undetectable in a second independent mouse experiment. 518 
These results suggest that in this animal model, with the route and vaccine dose used, EBOV-519 
VLP formation by a recombinant MVA vector did not significantly enhance the induction of 520 
EBOV-GP-specific antibodies or alter the IgG1/IgG2a isotype ratio compared to MVA-driven 521 
expression of EBOV-GP alone.  522 
 523 
GP-specific CD8 T cell response 524 
The EBOV-GP-specific CD8 T cell response following a prime-boost immunization regimen was 525 
analyzed in CBA/J mice, since the GP-derived CD8 T cell epitope inducing the strongest 526 
responses has been reported to occur in the H-2k haplotype. Shown is the GP-specific memory 527 
CD8 T cell response determined by intracellular staining of splenocytes for the cytokines IFN-γ, 528 
TNF-α and IL-2 as well as by surface staining of the degranulation marker CD107a at day 28 529 
after the last immunization. There was a moderately lower frequency of GP-specific CD8 T cells 530 
in the spleens of MVA-BN-EBOV-VLP immunized mice compared to MVA-BN-EBOV-GP. This 531 
moderate difference was statistically significant between the two groups immunized by the i.v. 532 
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route for most of the markers except IL-2 (Fig. 8), but not in mice immunized by the i.m. route. In 533 
contrast, the geometric mean fluorescence intensity of the signal for intracellular IFN-γ and 534 
TNF-α  was slightly higher in CD8 T cells of MVA-BN-EBOV-VLP immunized mice independent 535 
of the immunization route (Fig. 8). This difference was again statistically significant between the 536 
two i.v. immunized groups. Average total numbers of GP-specific CD8 T cells in the spleens of 537 
the two groups were similar (data not shown) reflecting the frequency results shown in Fig. 8. 538 
Frequencies of GP-specific CD8 T cells in blood on days 8 and 5 after prime and boost, 539 
respectively, determined by dextramer staining were also very similar between both groups 540 
independent of the immunization route (data not shown). In conclusion, the GP-specific CD8 T 541 
cell response induced by MVA-BN-EBOV-VLP was comparable to that induced by MVA-BN-542 
EBOV-GP. The slightly lower frequency of GP-specific T cells in the spleen induced by MVA-543 
BN-EBOV-VLP might be explained by the strong expression of the two additional potential CD8 544 
T cell targets, VP40 and NP. 545 
 546 
Discussion 547 
VLPs represent a vaccine modality with excellent immunogenicity and efficacy, as demonstrated 548 
by successful vaccination programs employing approved VLP-based vaccines for protection 549 
against hepatitis B and human papilloma virus-induced cervical cancer (45). With respect to 550 
filoviruses, EBOV-VLPs and MARV-VLPs have been shown to provide protection from EVD and 551 
MVD, respectively, in a number of animal models including the non-human primate (NHP) 552 
model (11,46-49), which represents the best available animal model for human EVD. Protection 553 
of NHPs was initially achieved with a three-dose immunization regimen and involved use of 554 
adjuvants (11,46). A follow-up study showed that two immunizations with adjuvanted ebolavirus 555 
VLPs are already sufficient to protect NHPs from EBOV challenge (49). In the present study, we 556 
generated and characterized a novel MVA-BN-based vaccine vector which simultaneously 557 
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expressed three ebolavirus proteins driving the formation of ebolavirus-like particles in vector 558 
infected cells. 559 
There is evidence from published literature showing that MVA might interfere with efficient 560 
transport of MARV-GP along the secretory pathway in human cells (50). Since budding of 561 
EBOV-VLPs takes place at the plasma membrane, such deficiency in transport competence 562 
might result in VLPs lacking GP. However, EBOV-GP expressed by MVA, either alone or in 563 
combination with VP40 and NP, was properly processed and transported to the cell surface, 564 
providing authentic GP antigen for VLP incorporation. In fact, the MVA-driven EBOV-VLPs were 565 
found to be decorated with GP spikes at high density (Fig. 4C, F), indicating that MVA did not 566 
interfere with incorporation of the viral glycoprotein into VLPs. 567 
Foreign envelope glycoproteins from HIV, murine leukemia virus and VSV have been shown to 568 
be co-packaged with EBOV-GP into retrovirus pseudotype particles because the viral GPs were 569 
recruited to the same assembly and budding sites at the plasma membrane (51). Interestingly, 570 
the poxvirus glycoprotein B5 was not detected in EBOV-VLPs in our study. Although B5 is able 571 
to reach the plasma membrane of vaccinia virus infected cells, it is actively retrieved from the 572 
cell surface and redirected to the Golgi compartment (39), where wrapping of mature poxviral 573 
particles with additional membranes takes place (52,53). Hence, poxviral and filoviral 574 
membrane-associated proteins accumulate and assemble at distinct cellular membrane 575 
compartments which explains why B5 is absent from EBOV-VLPs that were released from 576 
MVA-EBOV-VLP infected cells.  577 
The NP of filoviruses has been shown to accumulate in cytoplasmic inclusion bodies forming 578 
densely packed helical structures with a diameter of 20 - 25 nm (43,54). Using confocal 579 
immunofluorescence analysis, we observed similar inclusion bodies in cells infected with MVA-580 
BN-EBOV-VLP or following transfection of cells with plasmids encoding EBOV-VP40 and 581 
EBOV-NP. These inclusion bodies were intensely stained with antibodies specifically reacting 582 
with the respective NP (Fig. 2 and data not shown). In addition, ultrathin sections of MVA-BN-583 
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EBOV-VLP infected cells contained large aggregates consisting of nucleocapsid-like helical 584 
structures (data not shown). In contrast to some published reports (18,37), we did not observe 585 
redistribution of the homologous EBOV-NP from inclusion bodies to sites of EBOV-VP40 586 
accumulation at the plasma membrane when MVA infected cells were co-transfected with 587 
plasmids encoding EBOV-NP and EBOV-VP40 (data not shown). In addition, cells infected with 588 
MVA-BN-EBOV-VLP also showed large inclusion bodies consisting of NP (Fig. 2) similar to 589 
what has been reported for EBOV infected as well as MARV infected cells (54,55). Using a 590 
purely plasmid-driven system, Hoenen et al. also observed that inclusion bodies formed by NP 591 
in human Huh-7 cells remained stable when VP40 was co-expressed, and that rather some 592 
VP40 was associated with the NP inclusion bodies (56). We therefore assume that the complete 593 
resolution of the large NP inclusion bodies might require very strong VP40 expression that is 594 
apparently neither achieved in natural infection nor in most expression systems including ours. 595 
The fact that we did not observe resolution of NP inclusion bodies by VP40 co-expression does 596 
not exclude NP-VP40 interactions between a fraction of VP40 and NP molecules. Such 597 
interactions did apparently occur as evidenced by the incorporation of TAFV-NP as well as 598 
EBOV-NP into MVA-driven EBOV-VLPs (Fig. 3, 5) as well as by the productive infection of cells 599 
with EBOV and MARV despite persistence of NP inclusion bodies. 600 
VP40 is a major player in filovirus budding and VLP formation (12-15). Even if VLP formation is 601 
triggered by VP40 of MARV, i.e. a virus from a different filoviral genus, EBOV-GP is efficiently 602 
incorporated into VLPs (57). This finding is most likely attributable to the fact that a direct 603 
interaction of GP and VP40 is not required for GP incorporation into VLPs. Rather, GP is 604 
targeted to the same lipid raft domains that VP40 associates with (12,58,59). It has been shown 605 
in co-transfection experiments that EBOV-NP enhances the efficacy of homologous EBOV-606 
VP40-driven VLP formation and that it is incorporated into VLPs independently of GP (18,19). 607 
Incorporation of the RNP complex, of which NP is a major component, has been shown to occur 608 
in a genus-specific manner (60). 609 
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There is also evidence that NP and VP40 directly interact via both C-terminal and N-terminal 610 
domains of NP, with the C-terminus being most critical for packaging of nucleocapsids into 611 
EBOV particles (37,60). Since the NP amino acid sequences differ by at least 30% between 612 
ebolavirus species and sequence variations are most pronounced at the C-terminus, it was 613 
unclear whether packaging of a heterologous NP from a different ebolavirus species would 614 
occur. In the MVA-BN-EBOV-VLP construct investigated here, the gene encoding the 615 
heterologous TAFV-NP had been inserted to broaden the species coverage of the vaccine 616 
construct with respect to cellular immune responses. Our data suggest that both the 617 
heterologous TAFV-NP and the homologous EBOV-NP were able to enhance VLP formation 618 
(Fig. 3, 5). Western blot analyses suggested that both NPs were present in VLPs, whereas 619 
definite ring-like nucleocapsid structures in VLP cross-sections could only clearly be discerned 620 
by EM analysis when EBOV-NP was used (Fig. 6). Direct comparison of the EBOV-NP or 621 
TAFV-NP expression levels and presence in VLPs by Western blot was not feasible because 622 
different antibodies were required for detection. However, EGFP marker analysis and qPCR 623 
data indicated similar cellular expression levels of NPs. It will be of interest to determine 624 
whether the formation of nucleocapsid-like structures by TAFV-NP and EBOV-NP requires 625 
different viral cofactors, or whether TAFV nucleocapsids are morphologically distinct from EBOV 626 
nucleocapsids. 627 
The immune correlates of vaccine-induced protection against EVD are still not well defined, but 628 
multiple studies in NHPs as well as observations made with human EVD patients indicate that 629 
antibodies are important in protection against EVD (17,61). We therefore determined antibody 630 
responses induced by the MVA-BN-EBOV-VLP vaccine in mice (Fig. 7). Our basic analysis 631 
indicated that there was no significant difference in the amount of GP-specific binding or 632 
neutralizing antibodies or GP-specific IgG1/IgG2a isotype ratio induced by MVA-BN-EBOV-VLP 633 
compared to MVA-BN-EBOV-GP. However, the advantage of the VLP approach might reside in 634 
the quality of the vaccine antigen and thus the quality of the antibody response. Antibodies may 635 
 o
n
 April 5, 2017 by Universitaet Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
26 
 
 
protect from EVD by directly neutralizing the virus, but non-neutralizing antibodies can also be 636 
protective (62). One potential mechanism of protection by non-neutralizing antibodies may rely 637 
on the inhibition of filovirus particle release from cells (63). NK cell-mediated antibody-638 
dependent cellular cytolysis (ADCC), complement-mediated cell lysis and macrophage-639 
mediated antibody-dependent cellular phagocytosis (ADCP) might also contribute to protection 640 
by antibodies. Furthermore, mice are not known as natural hosts for filoviruses and the quality 641 
and quantity of antibodies induced by MVA-BN-EBOV-VLP in primates may show greater 642 
differences to those induced by MVA-BN-EBOV-GP than in mice. An investigation of the 643 
potential of MVA-BN-EBOV-VLP to induce antibodies that exert protective functions such as 644 
ADCC or ADCP is warranted.  645 
CD8 T cell responses are thought to contribute to protection against EVD, and MVA is 646 
recognized as a potent inducer of CD8 T cell responses. We found that the frequencies of GP-647 
specific CD8 T cells in the blood and in the spleen at different time points after immunization 648 
were very similar or possibly even somewhat lower in mice vaccinated with MVA-BN-EBOV-649 
VLP compared to vaccination with MVA-BN-EBOV-GP (Fig. 8 and data not shown). This slightly 650 
lower GP-specific response might have occurred due to the strong expression by the MVA-BN-651 
EBOV-VLP construct of two additional filoviral antigens, VP40 and NP, which are predicted to 652 
contain good CD8 T cell epitopes in the H-2k background. We did not attempt to define VP40- 653 
and NP-derived epitopes in this background, but should such immunogenic epitopes exist, it is 654 
conceivable that the CD8 T cell response against these antigens would compete with that 655 
against GP and would likely reduce the GP-specific response. A similar phenomenon was 656 
observed e.g. for the CD8 T cell response against the B8 MVA antigen that was reduced 657 
depending on the strength of early ovalbumine expression in the H-2b background (64). It is 658 
thus possible that the GP-specific CD8 T cell response induced by MVA-BN-EBOV-VLP might 659 
be similar or even higher without this competition effect compared to single GP expression. On 660 
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the other hand, the MVA-BN-EBOV-VLP vaccine construct could possibly induce a broader CD8 661 
T cell response against filovirus antigens. 662 
In summary, we found that the MVA vaccine vector allows efficient formation and release of 663 
bona fide GP-spiked EBOV-VLPs and efficiently induces GP-specific antibody and T cell 664 
responses. The MVA-filovirus VLP platform might be further armed with additional GP antigens 665 
derived from different ebolavirus species as well as from MARV to ultimately generate a 666 
multivalent and highly immunogenic pan-filovirus vaccine.  667 
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Figure legends 677 
Figure 1 678 
Cellular expression of ebolavirus GP, VP40 and NP driven by recombinant MVAs. 679 
(A) Schematic representation of MVA wild-type (MVA-BN) and MVA recombinants expressing 680 
Zaire ebolavirus glycoprotein (EBOV-GP) either alone (MVA-EBOV-GP) or in combination with 681 
the EBOV matrix protein VP40 (EBOV-VP40) and the Taï Forest ebolavirus nucleoprotein 682 
(TAFV-NP) (MVA-BN-EBOV-VLP). Expression cassettes were introduced into the MVA genome 683 
at intergenic regions (IGRs) (indicated as black arrows). The poxviral promoters PrS and PrS5E 684 
driving gene transcription of filoviral transgenes are indicated. (B, C, D) HeLa cells in 12-well 685 
plates were infected with the indicated viruses at a multiplicity of infection (MOI) of 10. (B) For 686 
Western blot analysis, cells were lysed at 6 h and 24 h p.i. in 150 µl of 1x Laemmli sample 687 
loading buffer. Cellular lysates prepared at 24 h p.i. were diluted 1:3 as indicated (*), separated 688 
by reducing SDS-PAGE, and transferred to PVDF membranes. Blots were incubated with anti-689 
GP antibody (mAb 6D8) and subsequently with anti-mouse IgG peroxidase conjugate. The 690 
immunoblots were developed with a standard chemiluminescent peroxidase substrate. (C) 691 
Analysis of N-glycosylation patterns of EBOV-GP. HeLa cells were lysed in 150 µl of 1x RIPA 692 
buffer at 17 h p.i. Protein lysates were treated with Endo H or PNGase F, or were left untreated 693 
(-). Following endoglycosidase treatment, the proteins were mixed with 3x Laemmli loading 694 
buffer, separated by reducing SDS-PAGE and analyzed by immunoblotting using an anti-GP 695 
antibody (mAb 6D8). The immunoblot was developed using an ECL detection system with 696 
enhanced sensitivity. (D) Flow cytometric analysis of EBOV-GP expression. At 4 h and 24 h p.i., 697 
HeLa cells were suspended in PBS/2% FCS and incubated with anti-EBOV-GP antibody (mAb 698 
6D8) and subsequently with anti-mouse IgG-allophycocyanin. Stained cells were analyzed by 699 
flow cytometry; cell surface expression of EBOV-GP is represented in histogram plots. (E) HEK 700 
293T/17 cells in 12-well plates were incubated for 2 h with the indicated viruses (MOI of 5). 701 
Thereafter, the inoculum was replaced with DMEM/2% FCS. One day after infection, adherent 702 
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cells were lysed in 1x Laemmli loading buffer and analyzed by immunoblotting using antibodies 703 
directed to EBOV-GP, EBOV-VP40 or TAFV-NP.  704 
 705 
Figure 2  706 
Intracellular distribution of EBOV-GP, EBOV-VP40 and TAFV-NP expressed by 707 
recombinant MVAs. 708 
HeLa cells infected with MVA-BN-EBOV-VLP (expressing EBOV-GP, EBOV-VP40 and TAFV-709 
NP), MVA-BN-EBOV-GP (expressing EBOV-GP alone) or MVA wt were fixed and 710 
permeabilized 6 h p.i. and incubated with either anti-EBOV-GP mAb 6D8 (green), polyclonal 711 
rabbit anti-EBOV-VP40 antibody (magenta) or with the polyclonal rabbit anti-TAFV-NP antibody 712 
(cyan). Antigen-bound primary antibodies were detected with Alexa Fluor-conjugated secondary 713 
antibodies and cells analyzed with an inverse confocal laser-scanning microscope. MVA vector 714 
infected cells were detected by either EGFP or RFP fluorescence (shown in grey). 715 
 716 
Figure 3  717 
Release of MVA-encoded EBOV-VLPs and incorporation of TAFV-NP. 718 
293T/17 cells in T75 cell culture flasks were infected (MOI of 10) with MVA-BN-EBOV-VLP 719 
(expressing EBOV-GP, EBOV-VP40 and TAFV-NP), MVA-BN-EBOV-GP (expressing EBOV-720 
GP alone) or MVA-BN wt. After two hours, the inoculum was replaced with DMEM/5% FCS.  721 
One day after infection, supernatants from infected cells were precleared (400 g for 5 min) and 722 
purified by centrifugation through a 20% sucrose cushion at 36,000 rpm in a Beckmann SW41 723 
rotor for 2 h. The adherent cells were scraped in PBS and lysed in 1x Laemmli sample loading 724 
buffer. Cell lysates (CL), precleared supernatants (SN) and VLP preparations (VLP prep) were 725 
analyzed by immunoblotting using antibodies directed to either EBOV-GP, EBOV-VP40 or 726 
TAFV-NP. Western blot images were acquired using Kodak BioMax Light Films (Sigma-Aldrich, 727 
Munich, Germany). 728 
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 729 
Figure 4 730 
Transmission electron microscopy (TEM) analysis of EBOV-VLPs in MVA-BN-EBOV-VLP 731 
infected cells and of concentrated VLP preparations. 732 
(A, B) TEM analysis of ultrathin sections. HeLa cells were infected with MVA-BN-EBOV-VLP (A) 733 
or MVA-BN (B) using an MOI of 10 and fixed 1 d p.i. with glutaraldehyde and osmium tetroxide 734 
and embedded in Epon. Ultrathin sections were stained with uranyl-acetate and lead citrate and 735 
analyzed by TEM. Scale bars: 0.2 µm. (C-H) Immuno-EM analysis of concentrated VLP 736 
preparations from supernatants of HeLa cells infected for 24 h at a MOI of 10 with MVA-BN-737 
EBOV-VLP (C, F), MVA-BN-EBOV-GP (D, G) and MVA-BN (E, H). (C, D, E) Samples were 738 
adsorbed to EM grids and incubated with anti-EBOV-GP mAb 6D8 and subsequently with 739 
secondary anti-mouse IgG antibody coupled to 18 nm colloidal gold. (F, G, H) Samples were 740 
adsorbed to EM grids and incubated with anti-EBOV-GP mAb 6D8 and polyclonal rabbit anti-741 
vaccinia B5 antibody. The antigen-bound primary antibodies were detected with anti-mouse IgG 742 
conjugated with 12 nm colloidal gold and anti-rabbit IgG antibody conjugated with 18 nm 743 
colloidal gold.  744 
 745 
Figure 5 746 
Release of MVA-expressed EBOV-VLPs and incorporation of NP. 747 
(A) HEK 293T/17 cells in 12-wells were infected with MVA-BN (MOI of 5) and subsequently 748 
transfected with plasmids encoding the indicated filoviral proteins under the control of a poxviral 749 
early/late promoter. After 17 h of infection/transfection, cell supernatants were filtered and 750 
concentrated using Amicon® Ultra 100K centrifugation columns according to the manufacturer’s 751 
instructions. The adherent cells were lysed in 250 µl 1x Laemmli sample loading buffer. Cell 752 
lysates (CL) and Amicon column-purified supernatants (pur-SN) were analyzed by 753 
immunoblotting using antibodies directed to either TAFV-NP, EBOV-VP40 or EBOV-NP. For 754 
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detection of TAFV-NP (lower panel) a chemiluminescent substrate with enhanced sensitivity 755 
was used. (B) For analysis of B5 expression, cells were treated as described above, an 756 
uninfected mock control was included as control. Western blot of CLs and pur-SNs was probed 757 
with a polyclonal rabbit anti-vaccinia B5 antibody. All Western blots images were acquired using 758 
ChemiDoc Touch System, images were analyzed and signals quantified with Image Lab™ 759 
Software. The data shown are representative for at least three independent experiments.  760 
 761 
Figure 6 762 
Transmission EM analysis of transfected VLP-producing cells.  763 
HeLa cells in 6-wells were infected with MVA-BN (MOI of 5) and subsequently transfected with 764 
plasmids encoding EBOV-VP40 and EBOV-NP (A) or EBOV-VP40 and TAFV-NP (B). At 12 h 765 
p.i., cells were harvested by scraping and fixed with 2.5% glutaraldehyde. Thin sections of fixed 766 
cells were prepared and analyzed by transmission EM. (A) The boxed areas of the 767 
microphotograph shown at higher magnification. Arrowheads indicate VLPs with an inner 768 
nucleocapsid-like structure appearing as a central ring (“bull´s eye”). A cross-section through a 769 
cellular filopodium is marked with an arrow. (B) Open arrow-heads point to “empty” VLP cross-770 
sections. Note that only VLPs clearly showing a dark outer boundary were exactly cut in the 771 
perpendicular plane and therefore can reveal an inner ring.  772 
 773 
Figure 7 774 
EBOV-GP-specific antibody responses in mice following immunization with MVA-BN-775 
EBOV-VLP.  776 
CBA/J mice (group size n=5) were immunized intramuscularly in the hind leg on days 0 and 28 777 
with either MVA-BN-EBOV-GP (GP) or MVA-BN-EBOV-VLP (VLP). Serum was sampled on 778 
days 21, 42, and 56 and analyzed by plaque reduction neutralization test 50 (PRNT50) using 779 
recombinant VSV-EBOV-GP as surrogate virus (A) and for antigen-binding antibodies by 780 
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EBOV-GP-specific ELISA for total IgG (B), IgG1 (C) and IgG2a (D). Differences were not 781 
statistically significant. The PRNT and ELISA results shown are from one of two representative 782 
independent experiments. * = analysis of pooled serum from five mice. 783 
 784 
Figure 8 785 
EBOV-GP-specific CD8 T cell responses in mice following MVA-BN-EBOV-VLP 786 
immunization.  787 
CBA/J mice (group size n=5) were immunized on days 0 and 28 with either MVA-BN-EBOV-GP 788 
(GP) or MVA-BN-EBOV-VLP (VLP) by the intramuscular (i.m.) or intravenous (i.v.) route. Mice 789 
were sacrificed at day 56 and spleen cell suspensions were re-stimulated in vitro with EBOV-790 
GP-derived peptide (TELRTFSI). Cells were stained for expression of CD4, CD8, CD44 and 791 
CD107a, production of  IFN-γ, TNF-α and IL-2 was analyzed after  intracellular cytokine staining 792 
by flow cytometry. Percentages of CD8 T cells expressing CD107a, IFN-γ, TNF-α or IL-2 are 793 
shown on the left, geometric mean fluorescence intensities (GMFI) of the signal for CD107a, 794 
IFN-γ, TNF-α and IL-2 are shown on the right. * = p < 0.05 by unpaired two-tailed Student's t 795 
test.  796 
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